Today, the Sr. VP of IP, CSO of Supernus Pharmaceuticals (NASDAQ: SUPN), Padmanabh Bhatt, sold shares of SUPN for $263.1K.
Following Padmanabh Bhatt’s last SUPN Sell transaction on January 16, 2015, the stock climbed by 49.3%. This is Bhatt’s first Sell trade following 4 Buy transactions.
See today’s analyst top recommended stocks >>
Based on Supernus Pharmaceuticals’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $90.43 million and quarterly net profit of $26.35 million. In comparison, last year the company earned revenue of $75.83 million and had a net profit of $17.37 million. SUPN’s market cap is $3.01B and the company has a P/E ratio of 44.01. Currently, Supernus Pharmaceuticals has an average volume of 1.26M.
Based on 4 analyst ratings, the analyst consensus is Strong Buy with an average price target of $59.25, reflecting a 1.0% upside.
Company insider trades are published daily on the SEC (Securities and Exchange Commission). DailyInsider’s proprietary algorithm analyzes these trades and selects the most attractive stocks based on influential insider trades each day. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy.
